Evidence map›Paper›PMID 34187558›Full record

ArticleInfectious diseases of poverty2021

Access to quality diagnosis and rational treatment for tuberculosis: real-world evidence from China-Gates Tuberculosis Control Project Phase III.

Zhi-Peng Li, Wen-Hui Mao, Fei Huang, Ni Wang, Li-Ping Ma, Li-Qun Zhang, Meng-Qiu Gao, Wei-Bing Wang, Qi Zhao, Sheng-Lan Tang

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases of poverty, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Zhi-Peng LiSchool of Public Health, Fudan University, 138 Yixueyuan Road, Shanghai, 20032, China.
Wen-Hui MaoDuke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC, 27710, USA.
Fei HuangChinese Center for Disease Control and Prevention, Beijing, China.
Ni WangChinese Center for Disease Control and Prevention, Beijing, China.
Li-Ping MaBeijing Chest Hospital, 97 Machang, Tongzhou, Beijing, China.
Li-Qun ZhangBeijing Chest Hospital, 97 Machang, Tongzhou, Beijing, China.
Meng-Qiu GaoBeijing Chest Hospital, 97 Machang, Tongzhou, Beijing, China. gaomqwdm@aliyun.com.
Wei-Bing WangSchool of Public Health, Fudan University, 138 Yixueyuan Road, Shanghai, 20032, China.
Qi ZhaoSchool of Public Health, Fudan University, 138 Yixueyuan Road, Shanghai, 20032, China. zhaoqi@shmu.edu.cn.ORCID http://orcid.org/0000-0003-0140-3920
Sheng-Lan TangDuke Global Health Institute, Duke University, 310 Trent Drive, Durham, NC, 27710, USA.
Beijing Chest Hospital · CNFudan University · CNChinese Center For Disease Control and Prevention · CNDuke University · US

Funding

Bill and Melinda Gates Foundation OPP1149395
6 · The paper itself

Abstract

backgroundChina has successfully reduced tuberculosis (TB) incidence rate over the past three decades, however, challenges remain in improving the quality of TB diagnosis and treatment. In this paper, we assess the effects of the implementation of "China National Health Commission (NHC) and Gates Foundation TB Prevention and Control Project" on the quality of TB care in the three provinces.

methodsWe conducted the baseline study in 2016 and the final evaluations in 2019 in the 12 selected project counties. We obtained TB patients' information from the TB Information Management System and reviewed medical records of TB cases in the TB designated hospitals. We compared TB diagnosis and treatment services with the national practice guideline and used Student's t-test and Pearson χ

resultsThe percentage of sputum smear-negative (SS-) patients taking culture or rapid molecular test (RMT) doubled between 2015 and 2018 (from 35% to 87%), and the percentage of bacteriologically confirmed pulmonary TB cases increased from 36% to 52%. RMT has been widely used and contributed an additional 20% of bacteriologically confirmed TB cases in 2018. The percentage of TB patients taking drug susceptibility tests (DST) also doubled (from 40% in 2015 to 82% in 2018), and the proportion of TB patients receiving adequate diagnosis services increased from 85% to 96%. Among all SS- TB patients, over 86% received the recommended diagnostic services at the end of the study period, an improvement from 75% prior to the project implementation. However, the proportion of TB patients treated irrationally using second-line anti-TB drugs (SLDs) increased from 12.6% in 2015 to 19.9% in 2018. The regional disparities remained within the project provinces, albeit the gaps between them narrowed down for almost all indicators.

conclusionsThe quality of TB diagnosis services has been improved substantially, which is attributable to the coverage of new diagnosis technology. However, irrational use of SLDs remains a concern after the project implementation.

Indexed as

TuberculosisTuberculosis, PulmonaryAntitubercular AgentsChinaHumansSputumAntitubercular AgentsDiagnosisEvaluationRapid molecular testSecond line drugsTreatmentTuberculosis

Identifiers

PMID34187558
PMCPMC8243738
OpenAlexW3174662881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.